MaaT Pharma (EPA:MAAT) CHMP rejection shifts attention to September appeal, cash runway
MaaT Pharma plans to ask for a re-examination of Xervyteg after European regulators rejected the drug. The French biotech’s lead asset will face another look in September, a move that could decide both the drug’s future and the company’s balance sheet.